Avenacy Announces Launch of Magnesium Sulfate in Water for Injection in the U.S. Market
May 14 2024 - 8:00AM
Business Wire
Represents the Company’s eighth product launch
since inception in October 2023
Avenacy, a specialty pharmaceutical company focused on supplying
critical injectable medications, today announced it has launched
Magnesium Sulfate in Water for Injection in the United States as
approved by the U.S. Food and Drug Administration. Magnesium
Sulfate in Water for Injection is indicated for the prevention and
control of seizures in preeclampsia and eclampsia, respectively.
When used judiciously, it effectively prevents and controls the
convulsions of eclampsia without producing deleterious depression
of the central nervous system of the mother or infant. However,
other effective drugs are available for this purpose.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240513704895/en/
(Photo: Business Wire)
Avenacy's Magnesium Sulfate in Water for Injection is available
in Ready-to-Use Premix IV bags in multiple formulations: 2g/50mL
(40mg/mL), 4g/100mL (40mg/mL), and 4g/50mL (80mg/mL). In line with
Avenacy’s mission to champion patient safety and streamline patient
care, Magnesium Sulfate in Water for Injection will feature the
Company’s highly differentiated packaging and labeling to support
accurate medication selection. Additionally, the Ready-to-Use
presentation is expected to help reduce dosing inaccuracies,
enhance patient safety, and streamline inventory.
“As a vital product for healthcare providers, Magnesium Sulfate
represents a large market opportunity for Avenacy, and we are
excited to deliver this ready-to-use product to hospitals all over
the country as a means to improve patient care,” said Jeff Yordon,
Co-Founder and CEO of Avenacy. “Since launching seven months ago,
we have seen very encouraging early traction of Avenacy’s products
in the market, and we are proud to be launching our eighth product
as we continue to scale up our business in order to meet demand for
our injectable medications.”
Avenacy will partner with Milla Pharmaceuticals Inc., (“Milla
Pharmaceuticals”), the U.S. subsidiary of global generic and
pharmacy service player A.forall (“A.forall”), to begin shipping
Magnesium Sulfate in Water for Injection to wholesale partners this
week. Milla Pharmaceuticals is part of Avenacy’s global network of
development and contract manufacturing partners that have undergone
successful FDA inspections based on cGMP standards.
“We're excited to work with Avenacy to introduce Magnesium
Sulfate in Water for Injection to the market,” said Erik Lazarich,
President of A.forall’s U.S. Operations, “Delivering this
ready-to-use product to hospitals nationwide is a key step in
improving patient care and advancing our mission of making
affordable medicines available to all.”
Magnesium Sulfate in Water for Injection had U.S. sales of
approximately $37.0 million for the twelve months ending in June
2023.1
Please see link for Full Prescribing Information.
1Source: IQVIA
About Avenacy
Avenacy is a U.S.-based specialty pharmaceutical company focused
on supplying critical injectable medications used to treat patients
in various medically supervised settings, from acute care hospitals
to outpatient clinics and physician offices. Through a rigorous and
optimized selection process, the Company is building out a pipeline
of high-quality FDA approved injectable products in order to ensure
a resilient portfolio that can meet the needs of today’s dynamic
drug supply chain. With an experienced team, commitment to quality
and reliability, and product offerings intended to facilitate safe
and efficient patient care, Avenacy strives to be a trusted partner
for essential medications.
Avenacy was launched in 2023 and is headquartered in Schaumburg,
IL. For more information, please visit http://www.avenacy.com/.
About Milla Pharmaceuticals, an A.forall company
Milla Pharmaceuticals Inc., an A.forall company, is engaged in
the development, licensing, acquisition, and commercialization of
generic prescription drugs for the U.S. market focused on niche
injectable and solution products for hospitals and clinics.
More info: Milla Pharmaceuticals & A.forall – Making
Affordable Medicines Available To All.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240513704895/en/
Media FTI Consulting Avenacy@fticonsulting.com